{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-25-000165","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.050511+00:00","generated_at":"2026-05-17T00:12:27.226045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PacBio Q3 revenue $38.4M, net loss narrows to $38M; consumables hit record $21.3M","bullets":["GAAP net loss $38.0M ($0.13 loss per share) vs $60.7M ($0.22) YoY; non-GAAP net loss $36.8M ($0.12).","Consumable revenue record $21.3M (+15% YoY); instrument revenue $11.3M (down 33% YoY).","Non-GAAP gross margin improved to 42% from 33% YoY; operating expenses cut to $53.9M from $62.4M.","Revio systems shipped 13 (vs 22); Vega systems shipped 32; cash and investments $298.7M.","Launched SPRQ-Nx chemistry to reduce sequencing costs up to 40%; Sequel II CNDx approved in China."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-25-000165","json":"https://secwatch.observer/filing/0001299130-25-000165.json","markdown":"https://secwatch.observer/filing/0001299130-25-000165.md","text":"https://secwatch.observer/filing/0001299130-25-000165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913025000165/0001299130-25-000165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913025000165/pacb-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:12:27.226045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}